Drug profile · INN
moxetumomab pasudotox
LUMOXITI
moxetumomab pasudotox (LUMOXITI) is a cd22 binding agent.
EMA: withdrawn Antineoplastic and immunomodulating agents (L01) L01X
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — moxetumomab pasudotox
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
moxetumomab pasudotox (LUMOXITI) is a cd22 binding agent.
Key facts
INN moxetumomab pasudotox
Brand LUMOXITI
Mechanism CD22 binding agent
Target B-cell receptor CD22
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01X
Mechanism of action
CD22 binding agent
Primary target: B-cell receptor CD22
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is moxetumomab pasudotox?
moxetumomab pasudotox (LUMOXITI) is a cd22 binding agent.
What is the brand name for moxetumomab pasudotox?
LUMOXITI is a marketed brand name for moxetumomab pasudotox. Check FDA Drugs@FDA for the current US label holder and prescribing information.